Emeline Brenard1, Charles Pilette1, Caroline Dahlqvist2, Benoît Colinet3, Florence Schleich4, Florence Roufosse5, Antoine Froidure6. 1. Service de Pneumologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate10 1200, Bruxelles, Belgium. 2. Service de pneumologie, CHU-UCL Namur, Université Catholique de Louvain , Ottignies-Louvain-la-Neuve, Belgium. 3. Service de Pneumologie, Grand Hôpital de Charleroi, Charleroi, Belgium. 4. Service de Pneumologie, CHU Liège, Université de Liège, Liège, Belgium. 5. Service de Médecine Interne, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium. 6. Service de Pneumologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate10 1200, Bruxelles, Belgium. antoine.froidure@uclouvain.be.
Abstract
INTRODUCTION: Idiopathic chronic eosinophilic pneumonia (ICEP) is an orphan lung disease characterized by concomitant systemic and local eosinophilia, along with bilateral lung infiltrates. Symptoms include dyspnea of subacute/chronic onset, cough, and general systemic signs. Although all patients do respond to oral corticosteroids, relapse rate is very high, which highlights the need for alternative therapies in case of relapsing ICEP. Mepolizumab is a fully humanized antibody directed against interleukin 5, a key growth factor of eosinophils. In the present study, we retrospectively studied the effect of off-label use of mepolizumab for relapsing ICEP. MATERIALS AND METHODS: All data from patients treated with mepolizumab for relapsing ICEP were included in our database and diagnoses were reviewed. We analyzed the effect of treatment on relapse rate, oral corticosteroids (OCS) use, and lung lesions on high-resolution computed tomography (HRCT). RESULTS: We included ten patients in the final analysis, with a median follow-up of 9 months after initiation of mepolizumab. Beside its expected effect on circulating eosinophils, treatment with mepolizumab was associated with a significant reduction of annual rate of exacerbations and a reduced consumption of corticosteroids. We also observed a remission of lung lesions on follow-up HRCT. CONCLUSIONS: In this open-label retrospective study, treatment of ICEP with mepolizumab was associated with a reduction of relapses, OCS use, and the disappearance of lung infiltrates.
INTRODUCTION:Idiopathic chronic eosinophilic pneumonia (ICEP) is an orphan lung disease characterized by concomitant systemic and local eosinophilia, along with bilateral lung infiltrates. Symptoms include dyspnea of subacute/chronic onset, cough, and general systemic signs. Although all patients do respond to oral corticosteroids, relapse rate is very high, which highlights the need for alternative therapies in case of relapsing ICEP. Mepolizumab is a fully humanized antibody directed against interleukin 5, a key growth factor of eosinophils. In the present study, we retrospectively studied the effect of off-label use of mepolizumab for relapsing ICEP. MATERIALS AND METHODS: All data from patients treated with mepolizumab for relapsing ICEP were included in our database and diagnoses were reviewed. We analyzed the effect of treatment on relapse rate, oral corticosteroids (OCS) use, and lung lesions on high-resolution computed tomography (HRCT). RESULTS: We included ten patients in the final analysis, with a median follow-up of 9 months after initiation of mepolizumab. Beside its expected effect on circulating eosinophils, treatment with mepolizumab was associated with a significant reduction of annual rate of exacerbations and a reduced consumption of corticosteroids. We also observed a remission of lung lesions on follow-up HRCT. CONCLUSIONS: In this open-label retrospective study, treatment of ICEP with mepolizumab was associated with a reduction of relapses, OCS use, and the disappearance of lung infiltrates.
Authors: Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich Journal: N Engl J Med Date: 2008-03-16 Impact factor: 91.245
Authors: Florence E Roufosse; Jean-Emmanuel Kahn; Gerald J Gleich; Lawrence B Schwartz; Anish D Singh; Lanny J Rosenwasser; Judah A Denburg; Johannes Ring; Marc E Rothenberg; Javed Sheikh; Ann E Haig; Stephen A Mallett; Deborah N Templeton; Hector G Ortega; Amy D Klion Journal: J Allergy Clin Immunol Date: 2012-10-04 Impact factor: 10.793
Authors: Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: Ian D Pavord; Elisabeth H Bel; Arnaud Bourdin; Robert Chan; Joseph K Han; Oliver N Keene; Mark C Liu; Neil Martin; Alberto Papi; Florence Roufosse; Jonathan Steinfeld; Michael E Wechsler; Steven W Yancey Journal: Allergy Date: 2021-09-16 Impact factor: 14.710
Authors: Christer Janson; Leif Bjermer; Lauri Lehtimäki; Hannu Kankaanranta; Jussi Karjalainen; Alan Altraja; Valentyna Yasinska; Bernt Aarli; Madeleine Rådinger; Johan Hellgren; Magnus Lofdahl; Peter H Howarth; Celeste Porsbjerg Journal: Eur Clin Respir J Date: 2022-03-02